ATE450251T1 - Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung - Google Patents

Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung

Info

Publication number
ATE450251T1
ATE450251T1 AT05783321T AT05783321T ATE450251T1 AT E450251 T1 ATE450251 T1 AT E450251T1 AT 05783321 T AT05783321 T AT 05783321T AT 05783321 T AT05783321 T AT 05783321T AT E450251 T1 ATE450251 T1 AT E450251T1
Authority
AT
Austria
Prior art keywords
dihydrosphingomyelin
methods
formulations containing
liposomal formulations
therapeutic agent
Prior art date
Application number
AT05783321T
Other languages
English (en)
Inventor
Pieter Cullis
Thomas Madden
Michael Hope
Steven Ansell
Barbara Mui
Sean Semple
Norbert Maurer
Original Assignee
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tekmira Pharmaceuticals Corp filed Critical Tekmira Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE450251T1 publication Critical patent/ATE450251T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
AT05783321T 2004-05-17 2005-05-16 Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung ATE450251T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57171204P 2004-05-17 2004-05-17
US63199704P 2004-11-30 2004-11-30
PCT/US2005/017054 WO2005120461A2 (en) 2004-05-17 2005-05-16 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE450251T1 true ATE450251T1 (de) 2009-12-15

Family

ID=35169836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05783321T ATE450251T1 (de) 2004-05-17 2005-05-16 Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung

Country Status (7)

Country Link
US (1) US7811602B2 (de)
EP (1) EP1750673B1 (de)
AT (1) ATE450251T1 (de)
AU (1) AU2005251691A1 (de)
CA (1) CA2566559C (de)
DE (1) DE602005018043D1 (de)
WO (1) WO2005120461A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
AU2005291807B2 (en) 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
EP1933813A4 (de) * 2005-10-11 2013-02-27 Univ Pittsburgh Sphingomyelin-liposome zur behandlung von hyperaktiven blasenstörungen
EP1959961A2 (de) * 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulierung aus unlöslichen kleinmoleküligen wirkstoffen in trägern auf fettbasis
HUE030903T2 (en) * 2006-04-25 2017-06-28 Univ California Administration of growth factors for the treatment of CNS disorders
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP2047856A4 (de) * 2006-08-04 2010-07-28 Snow Brand Milk Products Co Ltd Infektionshemmer
AU2008303023B2 (en) * 2007-09-27 2014-01-09 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2296696B1 (de) 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz
WO2010062697A2 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120016010A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521765A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた細胞内接着分子１（ＩＣＡＭ−１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411019A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
WO2010113983A1 (ja) * 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (de) * 2009-09-23 2012-08-01 Indu Javeri Verfahren zur herstellung von liposomen
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
CA2816925C (en) * 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2394640A1 (de) * 2010-05-21 2011-12-14 MediGene AG Verbesserte liposomale Formulierungen von lipophilen Verbindungen
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP3372684B1 (de) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
CA2853316C (en) 2011-10-25 2018-11-27 The University Of British Columbia Limit size lipid nanoparticles and related methods
ES2921724T1 (es) 2011-12-07 2022-08-31 Alnylam Pharmaceuticals Inc Lípidos biodegradables para la administración de agentes activos
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
EP2922529B1 (de) 2012-11-20 2019-03-13 Spectrum Pharmaceuticals, Inc. Verbessertes verfahren zur herstellung von in liposomen verkapseltem vincristin zur therapeutischen verwendung
WO2014089216A1 (en) * 2012-12-04 2014-06-12 Tekmira Pharmaceuticals Corporation In vitro release assay for liposome encapsulated vincristine
BR112015021791B1 (pt) 2013-03-08 2022-08-30 Novartis Ag Compostos de lipídio catiônico e composições de lipídios e farmacêuticas
EP2971013B1 (de) 2013-03-15 2020-08-19 The University Of British Columbia Lipidnanopartikel zur transfektion und zugehörige verfahren
US20140316154A1 (en) 2013-03-15 2014-10-23 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
EP4019506A1 (de) 2013-12-19 2022-06-29 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
CA3179824A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
JP6731912B2 (ja) 2014-09-05 2020-07-29 ノバルティス アーゲー 活性物質の送達用の脂質および脂質組成物
CA2990202A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
AU2017321892A1 (en) 2016-09-02 2019-02-28 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
CA3058127C (en) * 2017-03-31 2022-07-05 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
JPWO2019189133A1 (ja) * 2018-03-27 2021-03-18 日油株式会社 スフィンゴミエリン誘導脂質およびその製造方法
EP3811931A4 (de) 2018-06-20 2021-08-04 FUJIFILM Corporation Kombinationsarzneimittel mit liposomzusammensetzung zur verkapselung eines wirkstoffes und immuncheckpoint-inhibitor
JP7057434B2 (ja) 2018-10-01 2022-04-19 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN113924365A (zh) 2019-03-29 2022-01-11 迪克纳制药公司 用于治疗kras相关疾病或病症的组合物和方法
WO2020206314A1 (en) * 2019-04-03 2020-10-08 New York University Liposomes encapsulating adenosine
JP2022530678A (ja) 2019-05-03 2022-06-30 ディセルナ ファーマシューティカルズ インコーポレイテッド 短縮センス鎖を有する二本鎖核酸阻害剤分子
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021146488A1 (en) 2020-01-15 2021-07-22 Dicerna Pharmaceuticals, Inc. 4'-o-methylene phosphonate nucleic acids and analogues thereof
US20230338288A1 (en) * 2020-07-14 2023-10-26 The Research Foundation For The State University Of New York Asymmetric charged vesicles and methods of preparing and use thereof
EP4192505A1 (de) 2020-08-04 2023-06-14 Dicerna Pharmaceuticals, Inc. Systemische verabreichung von oligonukleotiden
TW202313032A (zh) 2021-05-24 2023-04-01 日商富士軟片股份有限公司 處置劑
JPWO2022250013A1 (de) 2021-05-24 2022-12-01
US20230241118A1 (en) 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5171578A (en) * 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
JP2792702B2 (ja) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 乾燥時に改善された安定性を示すリポソームの調製方法
US4957773A (en) * 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
WO1995012387A1 (en) * 1993-11-05 1995-05-11 Amgen Inc. Liposome preparation and material encapsulation method
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
EP0832271B8 (de) * 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
CA2202103C (en) * 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
AU765809B2 (en) * 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US20020041897A1 (en) * 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same

Also Published As

Publication number Publication date
WO2005120461A2 (en) 2005-12-22
CA2566559A1 (en) 2005-12-22
AU2005251691A1 (en) 2005-12-22
CA2566559C (en) 2014-05-06
EP1750673B1 (de) 2009-12-02
US20060008909A1 (en) 2006-01-12
WO2005120461A3 (en) 2006-03-16
US7811602B2 (en) 2010-10-12
DE602005018043D1 (de) 2010-01-14
EP1750673A2 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
IL260127B (en) mek inhibitors and methods of using them
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MX2007010996A (es) Nuevas composiciones de liposomas.
SE0202539D0 (sv) Compounds
SG164368A1 (en) Treatment of cancer
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
NO20063429L (no) Brusende oral opiat doseringsform
TW200508214A (en) Novel compounds
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
DE60222573D1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
SE0301653D0 (sv) Novel compounds
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
TW200736227A (en) New compounds III
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
UA87312C2 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
SE0401763D0 (sv) Compounds
DE60130659D1 (de) Therapeutische verbindungen und verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties